Market Cap$10.46B
P/E25.50x
PEG Ratio0.61
Div yield—
Beta1.74
ALGN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-30.14%
Price vs S&P 500 (4W)1.62%
PEG Ratio0.61
VGM Score53.78
P/E Ratio (Annual)25.50x
ALGN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $2.60 | $2.64 | +1.72%(+$0.04) | |
| Q1 2026 | $2.29 | $2.58 | +12.84%(+$0.29) | |
| Q4 2025 | $2.97 | $3.29 | +10.81%(+$0.32) | |
| Q3 2025 | $2.41 | $2.61 | +8.36%(+$0.20) | |
| Q2 2025 | $2.57 | $2.49 | -3.26%(-$0.08) |
ALGN Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.96
3.96
3.96
3.88
Industry Peers — Orthopedic & Prosthetic Devices(31)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
ALGNAlign Technology Inc | B | D | C | 2.5x | 10.3% | 69.0% | 13.2% | $147.31 |
| ISRGIntuitive Surgical Inc. | D | B | B | 13.7x | 18.2% | 66.7% | 31.3% | $426.70 |
| EWEdwards Lifesciences Corp | D | C | B | 7.7x | 6.7% | 77.8% | 18.2% | $86.60 |
| STESTERIS plc | C | C | B | 3.6x | 13.8% | 44.4% | 18.9% | $222.66 |
| ZBHZimmer Biomet Holdings, Inc. | B | C | B | 2.1x | 3.2% | 69.9% | 14.2% | $94.98 |
| SNNSmith & Nephew plc | B | C | C | 1.9x | 6.2% | 68.2% | 12.9% | $29.06 |
| MSAMine Safety Incorporated | C | C | B | 3.5x | 6.8% | 47.6% | 21.2% | $179.05 |
| ESTAEstablishment Labs Holdings Inc. | F | A | C | 7.2x | 20.0% | 70.5% | -7.6% | $59.18 |
| ENOVEnovis Corporation | B | D | C | 0.5x | -6.0% | 61.4% | -45.1% | $19.59 |
| CDRECadre Holdings, Inc. | B | C | C | 1.6x | 8.6% | 41.8% | 10.1% | $26.38 |
| AVRAnteris Technologies Global Corp. Common Stock | D | C | C | 263.0x | — | 75.0% | -4738.4% | $6.05 |
About Align Technology Inc
Align Technology dominates the clear aligner market with Invisalign, which controls over 90% market share since FDA approval in 1998 and can treat approximately 90% of malocclusion cases. The platform has achieved significant scale with 14+ million cumulative patients and treated over 2 million cases in 2022 alone. The company strengthens its ecosystem with iTero intraoral scanners, which capture digital impressions for over half of Invisalign treatments.